Conflict of Interest Policy for Members of ICER’s Voting Bodies

Members of ICER’s voting bodies, including CTAF, Midwest CEPAC, and New England CEPAC, excluding ex-officio members, cannot work for any public or private payers. Members, excluding ex-officio members, are expected to be free from financial conflicts of interest, and all members will be required to disclose financial ties to any private health care organization. While issues of financial influence will be handled on a case-by-case basis, as a guideline, members, excluding ex-officio members, may not have substantial financial interests in the health care industry, defined as the following:

  • A specific financial association, such as individual health care stock ownership (including those held by the member or anyone in the member’s household) in excess of $25,000 during the previous year from any one health care manufacturer or insurer (e.g., $25,000 holdings in XYZ healthcare manufacturer or $25,000 consultancy income from ABC health insurer).
  • Financial association, such as individual health care stock ownership (including those held by the member or anyone in the member’s household) in excess of $50,000 in aggregate during the previous year from health care manufacturers or insurers (e.g., $15,000 holdings in XYZ healthcare manufacturer, $15,000 in speaking fees from ABC health insurer, and $20,000 in consultancy income from 123 health insurer).

Recusal

Any member with a potential influence on judgment, including but not limited to, a personal experience with a particular technology or condition; or a political consideration, shall recuse themselves from voting at a public meeting. Any member with a direct financial association with the particular product or service being evaluated at a meeting shall also recuse themselves from voting at that meeting. “Direct financial association” is defined as individual health care stock ownership (including those held by the member or anyone in the member’s household) in or health care consultancy income from the manufacturer of the product being evaluated in excess of $5,000 during the previous year.